Abstract
Introduction: Eating Disorders (EDs) significantly impact quality of life and social functioning, with varying prevalence rates and a recent rise in diagnosis due to the COVID-19 pandemic. Anorexia Nervosa (AN) frequently co-occurs with Obsessive-Compulsive Disorder (OCD), and this comorbidity leads to more severe symptoms and poorer outcomes. Treatments like Cognitive Behavioural Therapy (CBT) and selective serotonin reuptake inhibitors (SSRIs) are commonly used, but tailored interventions are needed for patients with both conditions.
Material and Methods: The study utilized structured clinical assessment tools, psychometric scales, and psychopharmacological agents. Psychometric scales such as SCID-5-CV, EDI-3, EDE-Q, BUT, SCL-90, EDS, CIA, Y-BOCS-II, and CGI were employed for a comprehensive clinical evaluation at baseline and after six months. The assessment included information on the patient’s medical and family history, onset of eating disorder symptoms, and details of OCD-related symptoms.
Case Description: This case report describes an 18-year-old woman with severe OCD and restrictive anorexia nervosa (AN-r). Initially treated with sertraline and aripiprazole, her regimen was adjusted to include Fluvoxamine and Lurasidone to better manage symptoms. After six months of intensive monitoring and treatment, the patient showed significant improvement in both AN-r and OCD symptoms, achieving clinical remission and increased BMI.
Discussion: The co-occurrence of OCD and AN is complex and often more severe, requiring innovative treatment approaches. Lurasidone, though promising as an adjunctive treatment, needs further research to confirm its efficacy and develop comprehensivetreatment guidelines for patients with this comorbidity.
Read more click here
